Daval has provided a short explanation regarding why their Aimspro trial for secondary progressive multiple sclerosis was halted earlier this month at St. George's Hospital in England.
It seems that the mediciation must not be allowed to thaw prior to injection-- and that protocol was simply not being followed by the pharmacy at the hospital. This would have likely led to an invalid and misleading trial result, so Daval took action. We hope this information puts many minds at ease, as the trial results for Aimspro in optic neuritis were indeed quite promising.
From Daval:
"The trial was halted because of concerns over St Georges Hospital’s pharmacy allowing the product "Aimspro" to thaw. This was in breach of all instructions given by Daval International. All other treatment programmes are completely unaffected."
